-
Clovis Oncology Inc (NASDAQ: CLVS) shares
declined 14 percent to $30.77 after the company disclosed its oral presentation of the primary efficacy and safety data for
rucaparib from its NDA dataset at the 2016 ESMO Congress. The company indicated that the drug candidate is under FDA's priority
review for the treatment of monotherapy of advanced ovarian cancer in patients with BRCA-mutated tumors inclusive of germline
and somatic BRCA mutations. The submission date for PDUFA is February 23, 2017.
-
Idera Pharmaceuticals Inc (NASDAQ: IDRA) shares
dropped 13.3 percent to $1.89 after dropping 16.48 percent on Thursday.
-
Biostage Inc (NASDAQ: BSTG) shares declined 12.7
percent to $0.961 after the company issued a regulatory update on Cellspan Esophageal Implant.
-
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) shares
dropped 12.4 percent to $4.47 after surging 25.93 percent on Thursday.
-
Mistras Group Inc (NYSE: MG) shares declined 11.7
percent to $20.59 after the company reported weak revenue for the first quarter and cut its fiscal 2017 outlook.
-
Ruby Tuesday, Inc. (NYSE: RT) shares fell 11 percent
to $2.23 as the company posted a wider-than-expected loss for its first quarter on Thursday.
-
Solaredge Technologies Inc (NASDAQ: SEDG) shares
declined 9.5 percent to $15.59. Goldman Sachs downgraded SolarEdge Technologies from Neutral to Sell and lowered the price
target from $19.00 to $12.00.
-
H&E Equipment Services, Inc. (NASDAQ: HEES)
fell 9.3 percent to $15.80. UBS downgraded H&E Equipment to Sell.
-
Coupa Software Inc (NASDAQ: COUP) shares dropped
9.1 percent to $30.24 after gaining 84.89 percent on Thursday.
-
Tyson Foods, Inc. (NYSE: TSN) shares fell 8.8
percent to $67.85. Pivotal Research downgraded Tyson from Buy to Sell.
-
Honeywell International Inc. (NYSE: HON) shares
declined 8.6 percent to $105.68 after the company cut the upper end of its sales and earnings guidance range for 2016.
-
Merrimack Pharmaceuticals Inc (NASDAQ: MACK) fell
7.4 percent to $5.54. JP Morgan downgraded Merrimack Pharmaceuticals from Overweight to Neutral.
-
Acacia Communications, Inc. (NASDAQ: ACIA) shares
dropped 6.7 percent to $102.07. Acacia Communications priced its 4.5 million share offering at $100 per share.
-
First Solar, Inc. (NASDAQ: FSLR) shares fell 5.5
percent to $37.55. Goldman Sachs downgraded First Solar from Buy to Neutral and lowered the price target from $58.00 to $42.00.
-
Helen of Troy Limited (NASDAQ: HELE) shares
dropped 5.4 percent to $82.16. Helen of Troy reported stronger-than-expected results for its second quarter on Thursday.
-
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
shares fell 4.9 percent to $34.45. Morgan Stanley downgraded Alnylam Pharmaceuticals from Overweight to Equal-weight.
-
Exelixis, Inc. (NASDAQ: EXEL) fell 3.4 percent to
$12.73 after the company disclosed Phase 1 trial results for cabozantinib in combination with nivolumab in advanced
genitourinary tumors.
-
Actuant Corporation (NYSE: ATU) dropped around 3
percent to $23.29. Wells Fargo downgraded Actuant from Outperform to Market Perform.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.